沙雷普塔疗法削减了三分之一的劳动力,在对其基因疗法的安全关切之后暂停药物方案。 Sarepta Therapeutics cuts one-third of its workforce and pauses drug programs after safety concerns over its gene therapy.

Sarepta治疗技术公司(一家生物技术公司)正在裁员约500名员工或员工的三分之一,并将暂停若干药物方案,每年节省4亿多美元。 Sarepta Therapeutics, a biotech firm, is cutting its workforce by around 500 employees, or a third of its staff, and will pause several drug programs to save over $400 million annually. 这一举动是在两个病人死亡之后,Duchenne肌肉萎缩基因疗法Elevidys的安全担忧之后采取的。 This move follows safety concerns over its Duchenne muscular dystrophy gene therapy, Elevidys, after two patient deaths. 该公司将增加一个关于肝衰竭风险的黑盒警告,并正在为治疗制定一个新的免疫抑制疗法。 The company will add a black box warning for liver failure risk and is working on a new immune-suppressing regimen for the therapy.